

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION GUIDELINES

21st InaSH Scientific Meeting 2027

Original Research | Systematic Review and Meta-analysis | Case Report

Invitation

The Indonesian Society of Hypertension Scientific Meeting Committee invites clinicians, researchers, and healthcare professionals to submit original scientific work relevant to hypertension and related fields. All abstracts will be evaluated by the InaSH Scientific Committee based on scientific quality, originality, methodological rigor, relevance, and clarity.

General Policies

1. Abstracts must be prepared in accordance with the format and requirements stated in this guideline.
2. Abstracts must be submitted online through the official submission form at inashmeeting.id. Submissions sent by email, post, or other offline methods will not be accepted.
3. There is no limit to the number of abstracts that an author may submit.
4. Abstracts must be original and must not have been previously published in the same form.
5. The presenting author is responsible for ensuring that all co-authors have reviewed and approved the abstract before submission.
6. Submission indicates the authors' consent for review and inclusion in the official materials of the InaSH Scientific Meeting.
7. The abstract submission deadline and acceptance notification schedule will be announced on the official meeting website.

Abstract Categories and Scope

Abstracts may be submitted under one of the following scientific categories:

1. Original Research
2. Systematic Review and Meta-analysis
3. Case Report

Submissions should be relevant to hypertension and its related fields, including cardiovascular, renal, cerebrovascular, metabolic, maternal, population-based, preventive, and multidisciplinary care.

Formatting Requirements

1. **Language:** Abstracts must be written in clear and concise English, with accurate grammar and spelling.
2. **Title:** The title should be concise, informative, and written in sentence case. Font: Times New Roman, size 12, Bold.
3. **Authors:** List each author using first name or initials followed by family name. Font: Times New Roman, size 12.
4. **Affiliations:** State the department, institution or hospital, city, and country for all authors. Font: Times New Roman, size 10, Italic.
5. **Length:** The abstract body should contain with a maximum limit of 250 words. The title, authors' names, affiliations, and keywords are excluded from the word count. Font: Times New Roman, size 12.
6. **Keywords:** Up to five keywords may be provided. Font: Times New Roman, size 12, Italic.
7. **Abbreviations:** Define abbreviations at first use and limit their use whenever possible.
8. **Medication names:** Use generic names. Brand or commercial names should be avoided.
9. **Author identification:** Do not include authors' names, academic titles, affiliations, or identifying information within the abstract body.
10. **Excluded elements:** Tables, figures, images, references, and acknowledgements must not be included in the abstract.
11. **Proofreading:** Abstracts will be reviewed in the form in which they are submitted. Authors must proofread carefully before submission.

Abstract Structure

Original Research

Original research abstracts must use the following structured format:

1. **Background:** Briefly describe the clinical or scientific context of the study.
2. **Objective:** State the main purpose or research question.
3. **Methods:** Describe the study design, setting, participants, intervention or exposure, outcome measures, and statistical analysis, as applicable.
4. **Results:** Present the main findings using relevant numerical data. Statements such as "results will be presented" are not acceptable.
5. **Conclusion:** Provide a concise conclusion supported by the study results.

Systematic Review and Meta-analysis

Systematic reviews and meta-analyses must follow the principles of PRISMA 2020 for Abstracts and use the following structured format:

1. **Background:** Briefly describe the rationale for the review.
2. **Objective:** State the primary review question or objective.
3. **Methods:** Describe the eligibility criteria, information sources or databases searched, date of the last search, risk-of-bias assessment, and methods of data synthesis. Protocol registration details should be included, if available.
4. **Results:** Report the number of included studies and participants, the main findings, and relevant effect estimates with measures of uncertainty, where applicable.
5. **Conclusion:** Present an interpretation supported by the findings and identify the principal clinical implications.

The systematic review must be completed at the time of submission. Protocol-only submissions or abstracts stating that "results will be presented" will not be accepted. A meta-analysis is not mandatory when quantitative pooling is not methodologically appropriate.

Case Report

Case reports should follow the principles of the CARE Guidelines and use the following structured format:

1. **Background:** Explain the clinical relevance or uniqueness of the case.
2. **Case Illustration:** Describe the patient's presentation, relevant investigations, diagnosis, management, and clinical outcome.
3. **Discussion:** Highlight the clinical significance, challenges, and key learning points.
4. **Conclusion:** Summarize the principal clinical message of the case.

Ethical Considerations

Authors must ensure that all applicable ethical and patient-consent requirements have been fulfilled.

1. Systematic reviews and meta-analyses based exclusively on previously published aggregate data generally do not require ethical approval.
2. Research involving human participants, animals, identifiable health records, biological materials, or non-public individual-level data must comply with applicable institutional and national ethical requirements.
3. Case reports generally do not require ethics committee approval. However, written informed consent for presentation and publication should be obtained from the patient or legally authorized representative.
4. All patient-identifying information must be removed from the abstract and presentation materials.
5. Ethical approval letters, exemption documents, and informed-consent forms do not need to be uploaded during abstract submission. However, the Scientific Committee may request supporting documentation when necessary.
6. Authors are responsible for maintaining patient confidentiality and research integrity.
7. Relevant financial relationships, sponsorships, or potential conflicts of interest must be disclosed.
8. Plagiarism, data fabrication, duplicate submission, and other forms of scientific misconduct are strictly prohibited.

Review and Selection

1. All submitted abstracts will undergo review by the InaSH Scientific Committee. Abstracts will be evaluated based on:
2. scientific quality and originality;
3. methodological rigor;
4. relevance to hypertension and related fields;
5. clarity of presentation; and
6. clinical or scientific significance.
7. The Scientific Committee reserves the right to accept or reject an abstract and to determine the final presentation format.
8. Accepted abstracts may be assigned to the Young Investigator Award, Moderated Poster Presentation, or Poster Display.
9. Notification of acceptance and presentation instructions will be sent to the presenting author.
10. The decision of the Scientific Committee is final.

Registration and Presentation

1. The presenting author must complete registration for the InaSH Scientific Meeting after receiving the acceptance notification.
2. Failure to register by the specified deadline may result in withdrawal of the abstract from the scientific programme.
3. Each accepted abstract must be presented by one of the authors listed in the original submission.
4. Presenting authors must comply with the presentation schedule and technical instructions provided by the committee.
5. Changes to the presenting author must be communicated to and approved by the Scientific Committee.

Presentation Tracks and Awards

Young Investigator Award

1. The Young Investigator Award (YIA) is intended for young or non-established investigators.
2. Applicants must be younger than 40 years of age at the time of the meeting.
3. Only original research abstracts are eligible for YIA consideration.
4. Applicants must present their work in person during the designated YIA session.
5. Accepted e-posters will be displayed during the meeting. Presenters must submit an e-poster in the specific format which will be announced in the abstract classification announcement through the official website.
6. The winner will be announced during the closing ceremony of the InaSH Scientific Meeting.

Moderated Poster Presentation

1. Abstracts assigned to the Moderated Poster Presentation track must be presented in person during the designated moderated poster session.
2. Presenters must submit an e-poster in the specific format which will be announced in the abstract classification announcement through the official website.
3. Accepted e-posters will be displayed during the meeting.
4. Eligible moderated poster presentations may be considered for a Best Moderated Poster Presentation award.

The winner will be announced during the closing ceremony.

Poster Display

1. Abstracts assigned to the Poster Display track must be submitted as an e-poster in the specific format which will be announced in the abstract classification announcement through the official website.
2. A formal oral presentation is not required unless otherwise instructed by the committee.
3. Accepted e-posters will be displayed during the meeting.